Measuring the impact of zero-cases studies in evidence synthesis practice using the harms index and benefits index (Hi-Bi)

[1]  Chang Xu,et al.  Should studies with no events in both arms be excluded in evidence synthesis? , 2022, Contemporary clinical trials.

[2]  Jon-Michael E. Caldwell,et al.  A Method for Calculating the Fragility Index of Continuous Outcomes. , 2021, Journal of clinical epidemiology.

[3]  Lifeng Lin,et al.  A proposed framework to guide evidence synthesis practice for meta-analysis with zero-events studies. , 2021, Journal of clinical epidemiology.

[4]  G. Rosner,et al.  Meta-analysis of rare adverse events in randomized clinical trials: Bayesian and frequentist methods , 2020, Clinical trials.

[5]  C. Garritty,et al.  Cochrane Rapid Reviews Methods Group offers evidence-informed guidance to conduct rapid reviews , 2020, Journal of Clinical Epidemiology.

[6]  Lifeng Lin,et al.  Fragility index of network meta-analysis with application to smoking cessation data. , 2020, Journal of clinical epidemiology.

[7]  Lifeng Lin,et al.  Laplace approximation, penalized quasi-likelihood, and adaptive Gauss–Hermite quadrature for generalized linear mixed models: towards meta-analysis of binary outcome with sparse data , 2020, BMC Medical Research Methodology.

[8]  Lifeng Lin,et al.  Factors that impact fragility index and their visualizations. , 2020, Journal of evaluation in clinical practice.

[9]  Xin Sun,et al.  Exclusion of studies with no events in both arms in meta-analysis impacted the conclusions. , 2020, Journal of clinical epidemiology.

[10]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, International Coaching Psychology Review.

[11]  Lifeng Lin,et al.  P-value driven methods were underpowered to detect publication bias: analysis of Cochrane review meta-analyses. , 2019, Journal of clinical epidemiology.

[12]  Isabelle Boutron,et al.  The statistical significance of meta-analyses is frequently fragile: definition of a fragility index for meta-analyses. , 2019, Journal of clinical epidemiology.

[13]  H. Chu,et al.  Performance of Between-study Heterogeneity Measures in the Cochrane Library , 2018, Epidemiology.

[14]  Evangelos Kontopantelis,et al.  A comparison of one‐stage vs two‐stage individual patient data meta‐analysis methods: A simulation study , 2018, Research synthesis methods.

[15]  S. Cole,et al.  Empirical Comparison of Publication Bias Tests in Meta-Analysis , 2018, Journal of General Internal Medicine.

[16]  I. Onakpoya.  Rare adverse events in clinical trials: understanding the rule of three , 2018, BMJ Evidence-Based Medicine.

[17]  Theo Stijnen,et al.  A comparison of seven random‐effects models for meta‐analyses that estimate the summary odds ratio , 2018, Statistics in medicine.

[18]  C. Hutchinson,et al.  Tourniquet use for knee replacement surgery , 2017 .

[19]  Elena Kulinskaya,et al.  Beta‐binomial model for meta‐analysis of odds ratios , 2017, Statistics in medicine.

[20]  A. Iorio,et al.  Impact of including or excluding both-armed zero-event studies on using standard meta-analysis methods for rare event outcome: a simulation study , 2016, BMJ Open.

[21]  D. Moher,et al.  A scoping review of rapid review methods , 2015, BMC Medicine.

[22]  O Kuss,et al.  Statistical methods for meta‐analyses including information from studies without any events—add nothing to nothing and succeed nevertheless , 2015, Statistics in medicine.

[23]  Lisa Hartling,et al.  Quality of reporting in systematic reviews of adverse events: systematic review , 2014, BMJ : British Medical Journal.

[24]  Jos Kleijnen,et al.  What is a rapid review? A methodological exploration of rapid reviews in Health Technology Assessments. , 2012, International journal of evidence-based healthcare.

[25]  Haitao Chu,et al.  Bivariate random effects models for meta-analysis of comparative studies with binary outcomes: Methods for the absolute risk difference and relative risk , 2012, Statistical methods in medical research.

[26]  Michael O. Finkelstein,et al.  Meta-Analysis of 'Sparse' Data: Perspectives from the Avandia Cases , 2012 .

[27]  Joseph Beyene,et al.  Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data , 2007, BMC medical research methodology.

[28]  Alexander J Sutton,et al.  What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. , 2004, Statistics in medicine.

[29]  Nicola J Cooper,et al.  Meta-analysis of rare and adverse event data , 2002, Expert review of pharmacoeconomics & outcomes research.

[30]  Rolf Lefering,et al.  Probability of adverse events that have not yet occurred: a statistical reminder , 1995, BMJ.

[31]  R. Peto,et al.  Beta blockade during and after myocardial infarction: an overview of the randomized trials. , 1985, Progress in cardiovascular diseases.